Pharma Focus Asia

Genentech Discovered First Alecensa® Treatment for Early-Stage Lung Cancer

Genentech has discovered the first-ever Alecensa® (alectinib) for adjuvant treatment after tumour removal in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumours ≥ 4 cm or node positive).

Alecensa now stands as the first ALK inhibitor endorsed for individuals with ALK-positive early-stage NSCLC who have undergone tumour surgery. Its efficacy has shown remarkable results in patients, including those with CNS metastases. With this recent approval, these benefits can potentially reach individuals in the early stages of the disease.

Alecensa, a prescription medicine, is utilised in the treatment of NSCLC caused by an abnormal ALK gene. It serves as an adjuvant therapy to prevent lung cancer recurrence after surgical tumour removal or as a treatment option for metastatic lung cancer.

With an unparallelled 76 percent reduction in the risk of disease recurrence or death compared to chemotherapy, Alecensa substantially enhances the standard of care for those with early-stage ALK-positive lung cancer.

The approval of Alecensa is a significant milestone for newly diagnosed individuals with early-stage ALK-positive lung cancer, who were previously unable to access ALK-specific therapy. These patients, often diagnosed at a younger age, frequently face recurrence and have a heightened risk of brain metastases compared to other NSCLC types.

This significant advancement underscores the importance of all early-stage lung cancer patients undergoing testing for ALK and other recommended biomarkers to receive the most appropriate treatment tailored to their needs.

Cytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024